Top Story

Six chemotherapy cycles failed to improve outcomes in node-negative breast cancer

December 18, 2014

SAN ANTONIO — Patients with node-negative breast cancer who received six cycles of 5-fluorouracil, epirubicin and cyclophosphamide experienced similar DFS and OS as patients who received four cycles of doxorubicin and cyclophosphamide, according to results of a phase 3 study presented at the San Antonio Breast Cancer Symposium.

“[In the MA-5 trial, the NCIC Clinical Trials Group] administered a dose-intensified epirubicin program, and the RFS and OS results were encouraging,” Charles Edward Geyer, Jr., MD, FACP, associate director for clinical research at Virginia Commonwealth University Massey Cancer Center, said during his presentation. “Additionally, the French Adjuvant Study Group around that time had also evaluated their standard adjuvant regimen of FEC-50 and had shown that six cycles of therapy were more effective than three. So, at that time, we had two separate trials looking at different epirubicin schedules, both of which had seemed to be positive. It seemed reasonable at that time to compare [doxorubicin and cyclophosphamide] with one of those regimens. Since we were going to conclude the study in node-negative patients and include post-menopausal women, we chose the FEC-100 [chemotherapy regimen] because of its improved toxicity profile.”

thumbnail for video 3949008667001 Meeting News CoverageVideo

Data show encouraging advances in treatment of AML

December 17, 2014
SAN FRANCISCO – According to preliminary data presented at the ASH Annual Meeting and Exposition, FLT3 inhibitors have been shown to have a dramatic, positive…
In the Journals

More studies urged in managing posttreatment fatigue in thyroid cancer

December 17, 2014
A paucity of reliable trials exists to guide evidence-based management of posttreatment fatigue in thyroid cancer survivors, according to a systematic review published…
Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease In the Journals

Diagnostic lineage test differentiated independent primary NSCLC tumors from metastatic disease

December 17, 2014
An analysis of genomic rearrangements detected by a diagnostic lineage test helped determine whether multiple non–small cell lung cancer tumors were independent…
FDA approvals

FDA expands approval of Cyramza to include aggressive NSCLC

December 17, 2014
The FDA expanded the approved use of ramucirumab to include use in combination with docetaxel for second-line treatment of patients with metastatic non–small cell…
More News Headlines »
CME
Hot melanoma

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates - Monograph

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
Meeting News Coverage Video
IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

IBIS-I: Tamoxifen provides long-term protection for women at high risk for breast cancer

December 12, 2014
SAN ANTONIO — Erin W. Hofstatter, MD, director of the Breast Cancer Genetics and Prevention Program at Yale…
More »
CME
Activity cover

Targeted Therapy and Immunotherapy in the Management of Metastatic Melanoma: 2014 Updates

This activity is supported by an educational grant from Merck & Co., Inc.

Melanoma remains a challenging condition for clinicians. An array of targeted therapies and immunotherapy are in…
More »
morganatic-roan morganatic-roan